Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Uveal Melanoma

• Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
• Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
• Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
• Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma
• Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
• A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
• Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
• Neoadjuvant Darovasertib in Primary Uveal Melanoma
• Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
• Adjuvant Quisinostat in High-Risk Uveal Melanoma
• A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
• A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
• Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
• Tebentafusp-tebn With LDT in Metastatic UM
• PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases
• Neoadjuvant Tebentafusp for Uveal Melanoma
• Adjuvant Tebentafusp in High Risk Ocular Melanoma